Physician profile
Pablo Davanzo
NPI 1598892473
$6,090.34
in general payments reported to CMS, 2019-2025
23 companies · $622 in 2025
The $622 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $814 · 2021: $1,105 · 2022: $1,300 · 2023: $943 · 2024: $595 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,160.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,368.96 | 2019-2022 | |
| Abbvie INC. | $801.83 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $799.46 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $560.45 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $507.72 | 2019-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Alkermes, INC. | $415.25 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $337.20 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $320.58 | 2020-2024 | Caplyta |
| Allergan, INC. | $226.01 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.89 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $109.54 | 2020-2024 | Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $69.02 | 2022 | |
| Neurocrine Biosciences, INC. | $65.07 | 2020-2023 | Ingrezza |
| Jazz Pharmaceuticals INC. | $59.78 | 2021 | |
| Eisai INC. | $50.91 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $50.43 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $47.59 | 2019-2020 | |
| Boston Scientific Corporation | $39.24 | 2021-2022 | |
| Neuronetics, INC. | $38.24 | 2019 | |
| Idorsia Pharmaceuticals US INC | $23.48 | 2023 | Quviviq |
| Indivior INC. | $22.20 | 2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $22.04 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $11.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Davanzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.